In the BioHarmony Drug Report Database

"Preview" Icon

Mirabegron

Myrbetriq, Myrbetriq Granules, Betmiga (mirabegron) is a small molecule pharmaceutical. Mirabegron was first approved as Myrbetriq on 2012-06-28. It is used to treat overactive urinary bladder and urge urinary incontinence in the USA. It has been approved in Europe to treat overactive urinary bladder. The pharmaceutical is active against beta-3 adrenergic receptor. In addition, it is known to target beta-1 adrenergic receptor and beta-2 adrenergic receptor. Myrbetriq’s patents are valid until 2036-03-31 (FDA).

 

Trade Name

 

Betmiga
 

Common Name

 

mirabegron
 

ChEMBL ID

 

CHEMBL2095212
 

Indication

 

overactive urinary bladder, urge urinary incontinence
 

Drug Class

 

Beta 3 adrenoreceptor agonist

Image (chem structure or protein)

Mirabegron structure rendering